Frishman W H, Covey S
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
J Clin Pharmacol. 1990 May;30(5):412-21. doi: 10.1002/j.1552-4604.1990.tb03479.x.
Penbutolol and carteolol are two new long acting, nonselective beta-adrenergic blockers which have been approved for the treatment of systemic hypertension. Both drugs have intrinsic sympathomimetic activity (partial agonist activity), however, less than that seen with pindolol. They appear to cause less resting bradycardia than propranolol, have no effect on lipids and lipoproteins, and have favorable side effect profiles.
喷布洛尔和卡替洛尔是两种新型长效非选择性β肾上腺素能阻滞剂,已被批准用于治疗系统性高血压。两种药物都具有内在拟交感活性(部分激动剂活性),然而,比吲哚洛尔的活性要低。它们引起的静息性心动过缓似乎比普萘洛尔少,对脂质和脂蛋白无影响,且副作用情况良好。